Can You Drink Alcohol While Taking Methotrexate?

Light-to-moderate drinking does not appear to meaningfully increase the risk of liver damage for most people taking methotrexate. The largest study to directly measure the question found that consuming fewer than 14 standard UK units of alcohol per week carried an extremely low probability of clinically important liver harm. That said, the picture changes at higher intake levels, and individual risk factors can shift the equation, so the blanket “no alcohol at all” advice that many patients receive deserves a closer look.

Why Doctors Worry About This Combination

Methotrexate is processed through the liver, where it accumulates in a form that can deplete certain protective compounds in liver cells. Research on liver biopsies from rheumatoid arthritis patients showed that methotrexate stored in the liver was linked to reduced folate levels in the tissue, a change that may contribute to liver stress over time.¹ Alcohol is also processed through the liver and, at higher levels of intake, damages liver cells through its own separate mechanisms. The worry has always been that combining two liver-stressing agents would multiply the damage.

Much of the original alarm came from older treatment regimens. Methotrexate was once given daily and at higher doses than the weekly schedules used today for conditions like rheumatoid arthritis and psoriasis. Reports of serious liver scarring and even liver failure were more common under those protocols. A review in the World Journal of Hepatology noted that older case reports involving high or daily dosing drove most of the drug’s fearsome liver reputation, and that the risk under modern weekly dosing with folic acid supplementation is considerably less clear.² That same review found that current studies show roughly a doubling of the relative risk of mildly elevated liver enzymes in people on methotrexate, but no increased risk of severe or symptomatic liver disease.

What the Research Says About Drinking on Methotrexate

The most direct evidence comes from a large UK study that tracked over 11,000 rheumatoid arthritis patients on methotrexate and compared liver enzyme elevations (a condition called transaminitis, which signals liver stress) across different levels of alcohol intake. The headline findings were reassuring for light drinkers. Patients who drank between one and seven units per week had no increased risk of transaminitis compared to non-drinkers, and neither did patients drinking eight to fourteen units per week.³ The crude rates of liver enzyme problems were nearly identical between people who drank any amount of alcohol and those who abstained entirely.

The risk started climbing only at higher intake levels. Consuming between 15 and 21 units per week was associated with a possible increase in liver problems, while drinking more than 21 units per week nearly doubled the risk of transaminitis compared to non-drinkers.³ The researchers also ran a probability analysis and found that drinking below 14 units per week was associated with less than a one percent chance of a clinically important increase in liver risk.

A separate smaller study looking at both methotrexate and another rheumatic drug found no patterns suggesting that higher alcohol consumption influenced baseline or peak liver enzyme levels.⁴ That study’s authors questioned whether the strict alcohol bans in clinical guidelines were justified by the available evidence.

What Counts as “Light to Moderate”

The key study used UK alcohol units as its measure, where one unit equals about 8 grams of pure alcohol. That is roughly half a standard pint of ordinary-strength beer, a small glass of wine (about 125 ml at typical strength), or a single 25 ml measure of spirits. For reference, a large glass of wine at a restaurant is usually around 2 to 3 UK units, and a pint of stronger craft beer can be 3 or more.

The safety signal in the research held up to about 14 units per week. In US terms, that translates to roughly seven standard American drinks per week, since a US “standard drink” contains about 14 grams of alcohol, which is close to 1.75 UK units. So the comfortable zone the research describes is around one drink per day on average, or something close to it. This aligns with what many general health guidelines suggest for adults even without methotrexate in the picture.

The threshold where risk clearly climbed was above 21 UK units per week, equivalent to roughly 10 to 12 US standard drinks. That level of drinking would be considered heavy by most public health frameworks regardless of medication use. The gray area between 14 and 21 units showed a trend toward higher risk but did not reach clear statistical significance, making it harder to draw a firm line in that range.

Why Folic Acid Matters

Most people on methotrexate are also prescribed folic acid supplements, and this turns out to be relevant to the alcohol question. Methotrexate works in part by interfering with folate metabolism. The same mechanism that helps control inflammation and overactive immune responses also depletes folate in the liver, which appears to be connected to the drug’s liver toxicity. Folate supplementation counteracts this.

Reviews of the evidence have found that taking folate alongside methotrexate reduces the incidence of liver enzyme elevations and gastrointestinal side effects without weakening the drug’s therapeutic benefit.⁵ Both folic acid and folinic acid have been shown to lower the rate at which people discontinue methotrexate due to side effects.⁶ If you are on methotrexate and drinking even occasionally, making sure you are actually taking your prescribed folate is one of the simplest protective steps available. Some patients forget or skip it, not realizing that it is doing quiet but meaningful work to protect their liver.

When Extra Caution Makes Sense

The reassuring data on light drinking applies to patients who are otherwise in reasonable health and on standard weekly methotrexate doses. Several factors can shift the risk profile enough that even moderate drinking deserves more careful thought:

Pre-existing liver conditions: If you already have fatty liver disease, hepatitis B or C, or elevated liver enzymes before starting methotrexate, the baseline risk is higher. Adding any alcohol on top of that changes the calculus in ways the general population studies may not capture.
Other hepatotoxic medications: Many people on methotrexate also take other drugs that stress the liver, including certain anti-inflammatories and disease-modifying agents. The more liver burdens stacking up, the less room there is for alcohol.
Obesity and metabolic syndrome: Excess weight is itself a risk factor for liver fibrosis, and methotrexate appears to compound that risk. People with significant obesity may face a different risk equation than lean patients in the same studies.
Diabetes: Similar to obesity, diabetes is an independent risk factor for liver disease, and its presence alongside methotrexate narrows the safe margin for additional insults to liver tissue.
High cumulative doses: Patients who have been on methotrexate for many years and have accumulated large lifetime doses may have more subclinical liver changes than someone who started recently.

None of these factors automatically mean you cannot have a glass of wine. They mean your doctor’s advice needs to be tailored to your individual situation rather than drawn from a generic guideline.

The Problem With Blanket Alcohol Bans

For years, the standard medical advice has been total abstinence from alcohol while on methotrexate. The emerging research suggests this may be too strict for many patients, and the consequences of overly rigid advice are not trivial. A survey of 200 rheumatoid arthritis patients on methotrexate found that roughly 29 percent had skipped their methotrexate dose specifically because they wanted to have a few drinks.⁷ That is a striking number. Missing doses of a disease-modifying drug to have a social drink creates a real risk of disease flare, which can lead to joint damage and the need for stronger immunosuppressive therapy.

The same survey found a complicated relationship between belief and behavior. About a third of patients believed it was unsafe to drink on methotrexate yet drank anyway.⁷ Meanwhile, over half the patients surveyed thought drinking on the medication was safe. The overall picture is one of confusion and inconsistency, where patients are making their own decisions without clear, evidence-based guidance.

Some rheumatology teams have started shifting their approach. Rather than telling all patients to avoid alcohol entirely, they are giving more nuanced advice that acknowledges the evidence supporting safety at low-to-moderate levels while emphasizing the importance of never skipping methotrexate doses to accommodate drinking occasions. The logic is straightforward: a patient who understands that a small amount of alcohol is acceptable is less likely to miss a dose of the drug that is actually controlling their disease.

Monitoring Your Liver While on Methotrexate

Regardless of whether you drink, routine blood tests are a standard part of methotrexate therapy. Your doctor will check liver enzymes periodically, usually every few months, to catch any early signs of liver stress. The most commonly tracked markers are ALT and AST, enzymes that rise when liver cells are damaged. A research analysis comparing different monitoring approaches found that these enzymes, along with a composite scoring system called FIB-4 that factors in age and platelet counts, had modest but useful ability to detect methotrexate-related liver changes.⁸

If you do drink while on methotrexate, keep a few practical points in mind. Be honest with your doctor about how much you drink, because they are interpreting your liver enzyme results in that context. A mild enzyme bump in someone who has two glasses of wine a week is evaluated differently than the same bump in someone who drinks heavily. The monitoring system only works well when your doctor has accurate information. And if your enzyme levels trend upward, cutting back on alcohol is one of the first and simplest interventions before considering a change in your methotrexate dose or switching to a different drug.

Timing and Spacing Drinks Around Your Dose

A question that comes up frequently is whether timing matters: should you avoid alcohol on the day you take your methotrexate, or is spreading drinks throughout the week better than concentrating them? There is no strong clinical trial evidence specifically comparing different timing strategies. The pharmacology offers a reasonable framework, though. Methotrexate concentrations in the blood peak within a few hours of an oral dose and decline over the next day or two, with the liver doing most of the metabolic work during that window. Many rheumatologists informally suggest avoiding alcohol on the day of your methotrexate dose and possibly the day after, to reduce the overlap between the drug’s peak liver processing and alcohol’s own liver demands. This is a sensible precaution rather than a proven requirement.

The binge-versus-spread question also matters. The large UK study tracked weekly units rather than drinking patterns within a week, so it cannot definitively answer whether consuming the same number of weekly units in a single evening is worse than distributing them across several days. General liver physiology strongly suggests that concentrated intake is harder on the liver than the same total spread out. Two drinks on three separate evenings is almost certainly gentler than six drinks on one Friday night, even if the weekly total is identical. This advice holds for everyone, but it is worth keeping top of mind if your liver is already working through a weekly dose of methotrexate.

Psoriasis, Crohn’s, and Other Conditions

Most of the alcohol-and-methotrexate research has been conducted in rheumatoid arthritis patients, which raises the question of whether the findings extend to people taking methotrexate for other conditions. The drug is also widely prescribed for psoriasis, psoriatic arthritis, Crohn’s disease, lupus, and certain cancers, sometimes at different dose ranges.

Psoriasis patients may face a somewhat different risk profile for an indirect reason: psoriasis itself is associated with higher rates of fatty liver disease and metabolic syndrome, both of which independently affect liver health. People with severe psoriasis also tend to have higher average alcohol consumption than the general population, compounding the picture. The folate supplementation data includes psoriasis patients specifically, showing liver protection in that group as well.⁵ But the comorbidity profile means that blanket reassurance from rheumatoid arthritis studies should be applied carefully rather than automatically to psoriasis patients with multiple risk factors.

For oncology uses, methotrexate doses are often dramatically higher than those used in autoimmune diseases, and the liver toxicity profile at those doses is a fundamentally different conversation. Patients receiving high-dose methotrexate for cancer treatment should follow their oncologist’s specific guidance on alcohol, which is typically much more restrictive and based on a separate set of considerations from what applies to weekly low-dose users.